The estimated Net Worth of Charles S Berkman is at least $13.5 Milion dollars as of 3 February 2021. Mr. Berkman owns over 18,097 units of Ligand Pharmaceuticals stock worth over $2,979,920 and over the last 18 years he sold LGND stock worth over $8,478,997. In addition, he makes $2,027,170 as Senior Vice President, General Counsel oraz Secretary at Ligand Pharmaceuticals.
Charles has made over 25 trades of the Ligand Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 18,097 units of LGND stock worth $3,230,315 on 3 February 2021.
The largest trade he's ever made was exercising 37,331 units of Ligand Pharmaceuticals stock on 30 August 2013 worth over $653,666. On average, Charles trades about 4,474 units every 55 days since 2007. As of 3 February 2021 he still owns at least 28,906 units of Ligand Pharmaceuticals stock.
You can see the complete history of Mr. Berkman stock trades at the bottom of the page.
Charles S. Berkman J.D. serves as Senior Vice President, General Counsel, Secretary of the Company. Mr. Berkman joined our company in November 2001 and previously served as Associate General Counsel and Chief Patent Counsel for our company (and Secretary since March 2007). Prior to joining our company, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.
As the Senior Vice President, General Counsel oraz Secretary of Ligand Pharmaceuticals, the total compensation of Charles Berkman at Ligand Pharmaceuticals is $2,027,170. There are 3 executives at Ligand Pharmaceuticals getting paid more, with John Higgins having the highest compensation of $6,770,380.
Charles Berkman is 51, he's been the Senior Vice President, General Counsel oraz Secretary of Ligand Pharmaceuticals since 2018. There are 8 older and 7 younger executives at Ligand Pharmaceuticals. The oldest executive at Ligand Pharmaceuticals, Inc. is John Lamattina, 70, who is the Independent Director.
Charles's mailing address filed with the SEC is 3911 SORRENTO VALLEY BOULEVARD,, SUITE 110, SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... oraz Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include: